Note 14 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Research and development expense	$ 13,054	$ 9,522
General and administrative expense	4,912	3,248
Other income	1,333	1,983
Net loss	(16,633)	(10,787)
Personnel [Member]
Research and development expense	3,202	2,761
General and administrative expense	1,594	944
General [Member]
Research and development expense	1,210	999
General and administrative expense	1,611	1,225
Tovecimig [Member]
Research and development expense	6,677	4,497
CTX-471 [Member]
Research and development expense	699	679
CTX-8371 [Member]
Research and development expense	529	586
CTX-10726 [Member]
Research and development expense	737	0
Stock Based Compensation [Member]
General and administrative expense	$ 1,707	$ 1,079